Investigational Drug Information for MEDI4736
✉ Email this page to a colleague
What is the development status for investigational drug MEDI4736?
MEDI4736 is an investigational drug.
There have been 349 clinical trials for MEDI4736.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 5th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are forty-five US patents protecting this investigational drug and one international patent.
Summary for MEDI4736
| US Patents | 45 |
| International Patents | 1,007 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2019-09-05) |
| Vendors | 0 |
Recent Clinical Trials for MEDI4736
| Title | Sponsor | Phase |
|---|---|---|
| Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer | AstraZeneca | Phase 2 |
| Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer | Washington University School of Medicine | Phase 2 |
| Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer | AstraZeneca | Phase 2 |
Clinical Trial Summary for MEDI4736
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
US Patents for MEDI4736
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MEDI4736 | See Plans and Pricing | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago (Chicago, IL) | See Plans and Pricing |
| MEDI4736 | See Plans and Pricing | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy | MedImmune Limited (Cambridge, GB) | See Plans and Pricing |
| MEDI4736 | See Plans and Pricing | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. (Menlo Park, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MEDI4736
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MEDI4736 | Canada | CA2889182 | 2032-10-26 | See Plans and Pricing |
| MEDI4736 | European Patent Office | EP2911669 | 2032-10-26 | See Plans and Pricing |
| MEDI4736 | World Intellectual Property Organization (WIPO) | WO2014066834 | 2032-10-26 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
